Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of NaQuinate in Healthy Volunteers
NCT04036617Phase 1Unknown
- Sponsor
- Haoma Medica
- Start
- Jun 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in osteoporosis comparing NaQuinate with Placebo (2 arms). Primary endpoints: Safety assessed by Adverse Events at 8 weeks and Tolerability assessed by Adverse Events at 8 weeks. Status: unknown.
02
Drugs
naquinate
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT04036617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04036617.